Supply shortage · 11.09.2026
Supply shortage Denmark: Anatera 100 mg/ml injektionsvæske, opløsning
Affected country: Denmark · Reported period: End of August 2026 – Mid-September 2026 · Active ingredient: Fluorescein (Fluoresceinnatrium)
Notice context
A supply shortage has been recorded for Anatera 100 mg/ml injektionsvæske, opløsning in Denmark. The stated reason is “Quality problems”. The notice concerns the active ingredient Fluorescein (Fluoresceinnatrium) and is not identified as hospital-relevant.
This information describes the reported supply status and is not medical or pharmaceutical treatment advice. Availability, alternatives and further measures must be assessed for each individual case by the responsible pharmaceutical market participants.
Official shortage notice for Denmark. Responsibility and update procedures follow the information supplied by the relevant authority.
Check the official notice list →Implications for procurement and the supply chain
The notice for Anatera 100 mg/ml injektionsvæske, opløsning is a supply signal concerning Fluorescein (Fluoresceinnatrium) in Denmark. The published reason “Quality problems” determines which data should be verified first.
Because the published reason does not establish a reliable operational cause, availability, source, timing, product status and the supply route should be verified without adding an unsupported explanation.
Decision route for this supply case
- Confirm the notice, product identity, period and actual demand with the primary source and accountable market participants.
- Assess source, product status, timing, lawful sourcing route and any buffer stock without adding an unsupported cause.
- Document release, stock status, GDP evidence, warehousing and transport process, and escalation responsibility.
Inter-Pharma can structure the B2B case, potential sourcing and warehousing routes, and operational implementation. Clinical decisions, regulatory permissibility, product release and actual availability remain with the accountable parties.
Request a structured supply review →Operational shortage resilience: GDP warehousing and pharmaceutical storage
A resilient stock concept for Anatera 100 mg/ml injektionsvæske, opløsning requires prior verification of product status, demand, coverage and the permitted supply route.
Inter-Pharma combines GDP-oriented pharmaceutical storage in Czechia with batch and expiry control, FEFO, stock status, picking and dispatch preparation in its own Cheb operation.
Because the product name may indicate a temperature-sensitive dosage form, the product specification and any 2–8 °C requirement are assessed project by project; this is not a blanket capacity commitment.
Operational checks for this notice
- Match product identity using record Lægemiddelstyrelsen-ID 095644c6-b0ca-434d-a495-3d6fec8c7756, active ingredient, strength, dosage form and pack.
- Confirm the reported status and the period Ende August 2026 to Mitte September 2026 with the primary source and potential suppliers.
- Document demand, stock coverage, open orders and lawful alternative or sourcing routes for the specific case.
- Clarify temperature, batch, expiry, stock status, recipient authorisation and GDP evidence before cross-border supply.
Relevant services and specialist pages
The following B2B topics are particularly relevant when handling a shortage involving Anatera 100 mg/ml injektionsvæske, opløsning: